Company Overview
Company Type: Private Company
Website: www.augurex.com
Number of Employees: -
Year Founded: -
Total Amount Raised (CAD mm)†: 1.00
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Augurex Life Sciences Corp., a biotechnology company, develops biomarkers that are substances in the body, which inform patient conditions to assist in their diagnosis and to optimize therapy selection and patient management. It provides AGX-020, a biomarker that serves as a drug for the treatment of rheumatoid arthritis. The company is based in North Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Biln, Norma K.
Co-Founder and Chief Executive Officer
Marotta, Anthony 
Co-Founder and Chief Scientific Officer


Primary Industry Classification
Biotechnology


Primary Office Location
1423 Dempsey Road | North Vancouver, BC | V7K 1S7 | Canada
Phone: 778-839-3319   Fax: 604-988-1425

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Western Universities Technology Innovation Fund
Feb-06-2008
Minority
-
Seed


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-6-2008
Feb-6-2008
Private Placement
Target
Augurex Life Sciences Corp.
Western Universities Technology Innovation Fund

1.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-22-2018
Company Conference Presentations
Augurex Life Sciences Corp. Presents at Precision Medicine World Conference - Silicon Valley, Jan-22-2018 through Jan-24-2018
Oct-09-2012
Client Announcements
Augurex Life Sciences Corp. Announces Exclusive License Agreement with Quest Diagnostics Inc. for the Development of Arthritis Biomarker 14-3-3 as Testing Service in the U.S
Feb-28-2011
Company Conference Presentations
Augurex Life Sciences Corp. Presents at 9th Annual BioPartnering North America, Feb-27-2011 through Mar-01-2011
Jan-26-2010
Company Conference Presentations
Augurex Life Sciences Corp. Presents at BioPartnering North America, Jan-25-2010 04:45 PM
Feb-06-2008
Private Placements
Augurex Life Sciences Corp. announced that it has received CAD 1 million in funding from Western Universities Technology Innovation Fund and other investors.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:47 AM
Augurex Life Sciences Corp.
Augurex Life Sciences Corp. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Dec 10, 2018 06:08 AM
Augurex Life Sciences Corp.
Augurex Life Sciences Corp. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Sep 10, 2018 04:57 AM
Augurex Life Sciences Corp.
Augurex Life Sciences Corp. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Jun 25, 2018 06:38 AM
Augurex Life Sciences Corp.
Augurex Life Sciences Corp. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Mar 13, 2018 06:36 AM
Augurex Life Sciences Corp.
Augurex Life Sciences Corp. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Biln, Norma K.
Co-Founder and Chief Executive Officer
778-839-3319
604-988-1425

Marotta, Anthony 
Co-Founder and Chief Scientific Officer
778-839-3319
604-988-1425

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
